NRX Pharmaceuticals, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NRX Pharmaceuticals completed FDA review of its ANDA for preservative-free ketamine (NRX-100) with no major drug deficiencies; sole remaining item is manufacturer's attestation on vial connector, already submitted. Company raised $22.3M gross in public offering, now has $26.7M cash (vs. $7.8M at year-end 2025), and is manufacturing 5M doses for anticipated 2026 commercialization. Additionally, DARPA selected NRX as prime contractor for $11.5M+ SPARC-TMS trial of NRX-101 for depression, potentially expanding addressable market from ~1M to 15M patients.
Why this rating
ANDA near-final approval + $22.3M capital raise = ~39% of market cap raised; ketamine launch is transformational for micro-cap but regulatory approval still pending. DARPA funding non-dilutive but dependent on contracting completion.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.